Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy ...
Tango Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of precision oncology therapies. The company leverages synthetic lethality and genetic ...
Pablo Langesfeld lost his daughter and son-in-law when the Champlain Towers building collapsed in 2021. Now he’s suffering ...
A recently published study shows that cancer cells can trick the immune system into attacking them by mimicking a viral ...
4h
Why a potential anti-cancer agent stalled in trials: New enzyme insights may boost yield and purity
Researchers at the University of Bayreuth have, for the first time, deciphered key steps in the biosynthetic mechanism of the ...
New NCCN guidelines highlight personalized combo treatments and new options to help patients with advanced kidney cancer live ...
The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...
Corcept Therapeutics wins early FDA approval for Lifyorli in platinum-resistant ovarian cancer, boosting growth outlook.
Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next ...
The integrity of DNA and RNA is essential for every cell. DNA contains the genetic information for proteins, while RNA serves ...
A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks ...
NextGen Scientific issued an updated press release correcting inaccurate information about their $10 million private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results